CSF proteomic analysis of semorinemab Ph2 trials in prodromal-to-mild (Tauriel) and mild-to-moderate (Lauriet) Alzheimer’s disease identifies distinct trial cell-type specific proteomic signatures

Alyaa M. Abdel-Haleem, Ellen Casavant, Balazs Toth, Edmond Teng, Cecilia Monteiro, Nikhil J. Pandya, Casper C. Hoogenraad, Brad A. Friedman, Felix L. Yeh, Veronica G. Anania, Gloriia Novikova
doi: https://doi.org/10.1101/2024.04.11.24305670

Data Availability

Patient-level data will not be made available upon publication.

Back to top
Posted April 12, 2024.
Download PDF

Supplementary Material

Data/Code
Email
CSF proteomic analysis of semorinemab Ph2 trials in prodromal-to-mild (Tauriel) and mild-to-moderate (Lauriet) Alzheimer’s disease identifies distinct trial cell-type specific proteomic signatures
Alyaa M. Abdel-Haleem, Ellen Casavant, Balazs Toth, Edmond Teng, Cecilia Monteiro, Nikhil J. Pandya, Casper C. Hoogenraad, Brad A. Friedman, Felix L. Yeh, Veronica G. Anania, Gloriia Novikova
medRxiv 2024.04.11.24305670; doi: https://doi.org/10.1101/2024.04.11.24305670
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area